Meeting With FDA on Drug Shortages Requested by House Committee

Citing price controls on pharmaceutical companies and an increased reliance on offshore manufacturers, Republican leaders of the House Committee on Oversight & Accountability Friday have requested extensive documentation on the FDA’s actions to address the current drug shortage by the end of next week. 

In a letter to FDA Commissioner Robert Califf, Committee Chair James Comer (R-Ky.) and Subcommittee on Health Care and Financial Services Chairwoman Lisa McClain (R-Mich.) pointed to IRA-authorized price control provisions that reduce profitability for pharmaceuticals, and subsequently inhibit production and investment in new therapies. 

The letter also referenced the FDA’s list of 128 drugs currently in shortage, including commonly used medications that treat cancer, heart failure, infections and respiratory illnesses. Commonly-used acetaminophen and ibuprofen for children were also reported as being in shortage earlier this year. 

Read the letter to Califf here. 

To read the whole story, click here to subscribe.

Related Topics